Shamburg News · 8-K filed Nov 12, 2026, 8:10 AM EST
Theriva Biologics Reports Third Quarter 2026 Results and Completes SYN-004 Asset Sale
TOVX · Theriva Biologics, Inc.
- Earnings
- Material agreement
- Materiality: high
Theriva Biologics reported a net loss of $1,471 thousand, or $0.03 per share, for the quarter ended September 30, 2026, compared with a net loss of $4,361 thousand, or $0.45 per share, a year earlier. The company reported no license revenue for the quarter and cash and cash equivalents of $8.5 million as of September 30, 2026. The filing also states that the company completed the sale of its SYN-004 (ribaxamase) antibiotic-degrading enzyme portfolio to Biossil Labs Inc. in October 2026 for a $350,000 upfront payment.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-125912.
Written from the filing by Shamburg Markets. Figures are as reported by the company.